A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. - Wikidata - awgldk - TriplyDB

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.

http://www.wikidata.org/entity/Q33633625

about

Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials.

P2860

Q24235971-8F7C3B66-DFF6-48D2-8B8E-135A4CD82A4F Q34290335-7F0D880D-33FB-4E8B-93CE-94645BA2AE14

P2860

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.

http://www.wikidata.org/entity/Q33633625

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@ast

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@en

type

label

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@ast

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@en

prefLabel

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@ast

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@en

P1433

Q33633625-26500DCF-DE3C-4DE3-B6EF-95072F787C97

P1476

Q33633625-87DDA565-A61B-487D-BCCA-97BDFBD64F74

P2093

Q33633625-0BF90178-5C16-475B-8AB8-E1E409A81DDB

Q33633625-206CF4DF-C9BF-4E2A-9821-A230269B1975

Q33633625-4C7018AB-7653-4D19-A909-CAC7A386DB5D

Q33633625-679D2465-E8E2-451F-AB9F-B76DFA9BCCF2

Q33633625-B299579B-0E5B-4E22-A7E9-A144E0E462C3

Q33633625-C9E3B3BC-BC35-40D3-A9EB-39E037E51622

P2860

Q33633625-00D03A8D-E70D-46E4-8BB4-9C499529D6A6

Q33633625-1A8986CA-7E92-4F84-A058-0F6E63BBD207

Q33633625-2370EDC4-2C3D-4229-9ED6-5006495A26F6

Q33633625-2708E0C7-A838-47BC-8B82-213ACC958982

Q33633625-3529DA94-9A0E-457C-A706-76628AA44B7C

Q33633625-373702E6-74C7-422A-9CFF-040D5C08C34C

Q33633625-463FA486-ACC1-485B-A056-FDB2BD7E4403

Q33633625-65AD68D0-9E75-4D91-91AB-CEBACD8ED1C2

Q33633625-6CB1586B-F94D-40FC-9BB8-C3A61CF756E8

Q33633625-86159635-BF64-42BF-8D94-0EC45889E6B3

P304

Q33633625-296A4DAC-B524-44CC-A886-62697B7592A1

P31

Q33633625-ADF0F1F8-46B2-4ED2-9835-8B5EF3EDAD91

P356

Q33633625-81DA2B87-E864-402E-9250-1060DA307BB2

P433

Q33633625-2C08B450-45C9-4654-9F8C-20E0CA02F645

P478

Q33633625-BE335165-3CCE-4D45-AE99-6068E6FECD1B

P577

Q33633625-735E416B-EC8B-4F27-983E-6881E59BEF1D

P5875

Q33633625-8A11DBAD-EC8B-4F80-817F-D0AC7B2A44DF

P698

Q33633625-C101CDB4-093B-418B-8407-BF77296C060A

P921

Q33633625-120C4540-9427-4C91-A01D-9AA3E5268410

Q33633625-61FC9F27-2846-4E6D-ABC5-9201E868DDAD

P932

Q33633625-AF146B12-0650-49AD-8BBB-D9B93A4BCC31

P356

J.1753-5174.2007.00002.X

P1433

Archives of Drug Information

P1476

A Comparison of Cardiovascular ...... coxib, Ibuprofen, and Placebo.

@en

P2093

Christopher P Cannon

http://www.w3.org/2001/XMLSchema#string

Cong Chen

http://www.w3.org/2001/XMLSchema#string

John Viscusi

http://www.w3.org/2001/XMLSchema#string

Peter M Dibattiste

http://www.w3.org/2001/XMLSchema#string

Sean P Curtis

http://www.w3.org/2001/XMLSchema#string

Tuli Ahmed

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of Coronary Heart Disease Using Risk Factor Categories

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

C-reactive protein and other inflammatory risk markers in acute coronary syndromes

Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthrit

Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

P304

4-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1753-5174.2007.00002.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41435743

http://www.w3.org/2001/XMLSchema#string

P698

20157362

http://www.w3.org/2001/XMLSchema#string

P921

P932

2817438

http://www.w3.org/2001/XMLSchema#string